- |||||||||| ebselen (SPI-1005) / Sound Pharma, selenomethionine (SLM) / Holden Comprehensive Cancer Center, The University of Iowa
Journal: Selenium Attenuates Ethanol-induced Hepatocellular Injury by Regulating Ferroptosis and Apoptosis. (Pubmed Central) - Oct 16, 2024
The process of ethanol damage to hepatocytes is regulated by the ferroptosis pathway. Selenium may exert a beneficial role in ethanol-induced hepatocyte injury by antagonizing oxidative stress and regulating apoptosis and ferroptosis pathways.
- |||||||||| selenomethionine (SLM) / Holden Comprehensive Cancer Center, The University of Iowa
Journal, IO biomarker: Selenomethionine Suppress the Progression of Poorly Differentiated Thyroid Cancer via LncRNA NONMMUT014201/miR-6963-5p/Srprb Pathway. (Pubmed Central) - Sep 20, 2024
In conclusion, selenomethionine and BS improved meat quality and flavor in broilers under heat stress by modulating muscle fiber composition and characteristics, as well as increasing intramuscular fat deposition. Collectively, SeMet inhibits the growth of PDTC in a dose-dependent manner through LncRNA NONMMUT014201/miR-6963-5p/Srprb signal pathway, thus suggesting that SeMet might be a potential drug for PDTC treatment.
- |||||||||| selenomethionine (SLM) / Holden Comprehensive Cancer Center, The University of Iowa
Journal: Study on Selenium Assimilation and Transformation in Radish Sprouts Cultivated Using Maillard Reaction Products. (Pubmed Central) - Sep 14, 2024
Maillard reactions were simulated using selenoamino acids (SeAAs; selenomethionine and methylselenocysteine) and reducing sugars (glucose and fructose) for preparing Se-MRPs...However, glucose and fructose seemed to inhibit the transformation of the Se-MRPs to SeAAs by 10.0 to 59.1% compared to purified Se-MRPs. These results provide key references for the efficient utilization of organic Se in the cultivation of Se-enriched sprouts.
- |||||||||| selenomethionine (SLM) / Holden Comprehensive Cancer Center, The University of Iowa
Journal: Alleviation of cadmium toxicity in soybean (Glycine max L.): Up-regulating antioxidant capacity and enzyme gene expressions and down-regulating cadmium uptake by organic or inorganic selenium. (Pubmed Central) - Sep 14, 2024
These results provide key references for the efficient utilization of organic Se in the cultivation of Se-enriched sprouts. Although much interest has been focused on the role of selenium (Se) in plant nutrition over the last 20 years, the influences of organic selenium (selenomethionine; Se-Met) and inorganic selenium (potassium selenite; Se-K) on the growth and physiological characters of cadmium (Cd)-stressed Glycine max L.) seedlings have not yet been studied...From the current results, we conclude Se-Met could represent a promising strategy to contribute to the development and sustainability of crop production on soils contaminated with Cd at a concentration of up to 1.0
- |||||||||| selenomethionine (SLM) / Holden Comprehensive Cancer Center, The University of Iowa
Journal: The effect of selenium on the intestinal health of juvenile grass carp based on the ERS-autophagy pathway. (Pubmed Central) - Sep 12, 2024
Although much interest has been focused on the role of selenium (Se) in plant nutrition over the last 20 years, the influences of organic selenium (selenomethionine; Se-Met) and inorganic selenium (potassium selenite; Se-K) on the growth and physiological characters of cadmium (Cd)-stressed Glycine max L.) seedlings have not yet been studied...From the current results, we conclude Se-Met could represent a promising strategy to contribute to the development and sustainability of crop production on soils contaminated with Cd at a concentration of up to 1.0 The 2160 healthy juvenile grass carp (9.76
- |||||||||| selenomethionine (SLM) / Holden Comprehensive Cancer Center, The University of Iowa
Journal: Selenium Supplementation Sensor Based on Direct Electrochemistry of Urinary Selenosugar and Total Selenium. (Pubmed Central) - Jul 23, 2024
Upon systematic standardization directed by Ramaley's theory, SeSE was integrated into a battery-operated portable kit (dubbed "SeEye") with a micro electrochemical drive and tablet PC console for one-stop service trials in a local commercial scenario. This study establishes (1) a nutritive value classifier in a low-cost consumer electronic format and (2) noninvasive diagnostic technology for Se supplementation.
- |||||||||| selenomethionine (SLM) / Holden Comprehensive Cancer Center, The University of Iowa
Journal: The effect of hydroxy-selenomethionine on the productive and reproductive performance of old broiler breeders. (Pubmed Central) - Jul 10, 2024
Additionally, it was found that with the increase in TaSBP-A gene overexpression levels in transgenic wheat, the transfer coefficient of Se from flag leaves to grains also increased. Therefore, using OH-SeMet may be a practical approach to help old broiler breeders' production and reproduction performance.
- |||||||||| Inlyta (axitinib) / Pfizer
Phase classification, Metastases: SLM + Axitinib for Clear Cell RCC (clinicaltrials.gov) - Jul 8, 2024
P1, N=46, Active, not recruiting,
Therefore, using OH-SeMet may be a practical approach to help old broiler breeders' production and reproduction performance. Phase classification: P1/2 --> P1
- |||||||||| selenomethionine (SLM) / Holden Comprehensive Cancer Center, The University of Iowa
Journal: Nano-Se exhibits limited protective effect against heat stress induced poor breast muscle meat quality of broilers compared with other selenium sources. (Pubmed Central) - Jul 7, 2024
Through comparing the meat quality, Se deposition, muscle fiber type conversion, glycolysis, mitochondrial homeostasis, and mitochondrial TCA cycle-related indicators of breast muscle in heat stressed broilers, we found that the protective effects of organic Se (SeY and SeMet) are better than that of inorganic Se (SS) and NanoSe. As a new Se source, though NanoSe showed some protective effect on breast muscle meat quality of heat stressed broilers, the protective effect of NanoSe is not ideal, compared with other Se sources.
- |||||||||| Inlyta (axitinib) / Pfizer
Trial completion date, Trial primary completion date, Metastases: SLM + Axitinib for Clear Cell RCC (clinicaltrials.gov) - Aug 25, 2023
P1/2, N=46, Active, not recruiting,
As a new Se source, though NanoSe showed some protective effect on breast muscle meat quality of heat stressed broilers, the protective effect of NanoSe is not ideal, compared with other Se sources. Trial completion date: Dec 2023 --> May 2026 | Trial primary completion date: Dec 2023 --> Jun 2023
- |||||||||| Inlyta (axitinib) / Pfizer
Enrollment closed, Metastases: SLM + Axitinib for Clear Cell RCC (clinicaltrials.gov) - Aug 24, 2023
P1/2, N=46, Active, not recruiting,
Trial completion date: Dec 2023 --> May 2026 | Trial primary completion date: Dec 2023 --> Jun 2023 Recruiting --> Active, not recruiting
- |||||||||| Inlyta (axitinib) / Pfizer
Trial completion date, Trial primary completion date, Metastases: SLM + Axitinib for Clear Cell RCC (clinicaltrials.gov) - Jul 28, 2023
P1/2, N=46, Recruiting,
Recruiting --> Active, not recruiting Trial completion date: Jun 2023 --> Dec 2023 | Trial primary completion date: Jun 2023 --> Dec 2023
- |||||||||| Inlyta (axitinib) / Pfizer
Trial primary completion date, Metastases: SLM + Axitinib for Clear Cell RCC (clinicaltrials.gov) - Aug 23, 2022
P1/2, N=46, Recruiting,
Trial completion date: Jun 2023 --> Dec 2023 | Trial primary completion date: Jun 2023 --> Dec 2023 Trial primary completion date: Jun 2022 --> Jun 2023
- |||||||||| Inlyta (axitinib) / Pfizer
Trial primary completion date, Metastases: SLM + Axitinib for Clear Cell RCC (clinicaltrials.gov) - Aug 18, 2021
P1/2, N=46, Recruiting,
Trial primary completion date: Jun 2022 --> Jun 2023 Trial primary completion date: Jun 2021 --> Jun 2022
- |||||||||| Inlyta (axitinib) / Pfizer
Enrollment change, Metastases: SLM + Axitinib for Clear Cell RCC (clinicaltrials.gov) - Nov 3, 2020
P1/2, N=46, Recruiting,
Trial primary completion date: Jun 2021 --> Jun 2022 N=35 --> 46
- |||||||||| Inlyta (axitinib) / Pfizer
Trial primary completion date, Metastases: SLM + Axitinib for Clear Cell RCC (clinicaltrials.gov) - Mar 16, 2020
P1/2, N=35, Recruiting,
N=35 --> 46 Trial primary completion date: Jun 2020 --> Jun 2021
- |||||||||| Inlyta (axitinib) / Pfizer
Phase classification, Metastases: SLM + Axitinib for Clear Cell RCC (clinicaltrials.gov) - Jun 20, 2019
P1/2, N=35, Recruiting,
Trial primary completion date: Jun 2020 --> Jun 2021 Phase classification: P1 --> P1/2
- |||||||||| Inlyta (axitinib) / Pfizer
Enrollment open, Trial completion date, Trial primary completion date, Metastases: SLM + Axitinib for Clear Cell RCC (clinicaltrials.gov) - Mar 19, 2019
P1, N=30, Recruiting,
Phase classification: P1 --> P1/2 Trial completion date: Sep 2020 --> Jun 2023 | Trial primary completion date: Sep 2019 --> Jun 2020 | Suspended --> Recruiting
- |||||||||| Inlyta (axitinib) / Pfizer
Trial completion date, Trial primary completion date, Metastases: SLM + Axitinib for Clear Cell RCC (clinicaltrials.gov) - Aug 8, 2018
P1, N=30, Recruiting,
Trial completion date: Sep 2020 --> Jun 2023 | Trial primary completion date: Sep 2019 --> Jun 2020 | Suspended --> Recruiting Trial completion date: Sep 2019 --> Sep 2020 | Trial primary completion date: Sep 2018 --> Sep 2019
- |||||||||| Inlyta (axitinib) / Pfizer
Enrollment open, Metastases: SLM + Axitinib for Clear Cell RCC (clinicaltrials.gov) - Nov 9, 2016
P1, N=30, Recruiting,
Trial completion date: Sep 2019 --> Sep 2020 | Trial primary completion date: Sep 2018 --> Sep 2019 Suspended --> Recruiting
- |||||||||| Inlyta (axitinib) / Pfizer
Trial suspension, Metastases: SLM + Axitinib for Clear Cell RCC (clinicaltrials.gov) - Oct 26, 2016
P1, N=30, Suspended,
Suspended --> Recruiting Recruiting --> Suspended
- |||||||||| Inlyta (axitinib) / Pfizer
Enrollment open, Metastases: SLM + Axitinib for Clear Cell RCC (clinicaltrials.gov) - Jan 27, 2016
P1, N=30, Recruiting,
Recruiting --> Suspended Active, not recruiting --> Recruiting
- |||||||||| Inlyta (axitinib) / Pfizer
Enrollment closed, Trial initiation date, Metastases: SLM + Axitinib for Clear Cell RCC (clinicaltrials.gov) - Jan 25, 2016
P1, N=30, Active, not recruiting,
Active, not recruiting --> Recruiting Not yet recruiting --> Active, not recruiting | Initiation date: Sep 2015 --> Jan 2016
|
